Physician profile
Paul Celano
NPI 1649222845
$5,800.27
in general payments reported to CMS, 2019-2025
42 companies · $1,748 in 2025
The $1,748 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2020: $1,087 · 2021: $1,992 · 2022: $39.41 · 2023: $256 · 2024: $132 · 2025: $1,748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,978 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,978.38 |
| Education | $158.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,987.63 | 2021-2025 | Jemperli, Zejula |
| Bayer Healthcare Pharmaceuticals INC. | $963.40 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $282.51 | 2019-2025 | Calquence, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $234.28 | 2019-2025 | Opdivo, Opdualag |
| Gilead Sciences, INC. | $211.07 | 2021-2025 | Trodelvy |
| Astellas Pharma US INC | $209.55 | 2019-2025 | Vyloy |
| Daiichi Sankyo INC. | $191.78 | 2019-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $158.96 | 2019-2025 | Keytruda, Reblozyl, Keytruda Qlex |
| Abbvie INC. | $151.32 | 2019-2025 | Venclexta |
| Janssen Biotech, INC. | $151.26 | 2019-2025 | Rybrevant, Tecvayli, Talvey |
| Novartis Pharmaceuticals Corporation | $129.67 | 2025 | |
| Celgene Corporation | $112.04 | 2025 | Reblozyl |
| Exelixis INC. | $107.15 | 2019-2025 | Cabometyx |
| Aveo Pharmaceuticals, INC. | $104.50 | 2023-2025 | Fotivda |
| Pfizer INC. | $101.62 | 2019-2025 |
Show all 39 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Celano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.